Navigate the Complexity of Modern Evidence Synthesis
In modern health economics and outcomes research (HEOR), selecting the right Indirect Treatment Comparison (ITC) is no longer just a technical detail but a critical driver of regulatory success, HTA submissions, and market access.
As clinical trial networks grow more complex and heterogeneous, relying on a one-size-fits-all approach to evidence synthesis risks compromising the credibility of your comparative effectiveness estimates.
The question remains:
How do you confidently choose between traditional NMA, population-adjusted methods like MAIC and STC, or advanced frameworks like ML-NMR and External Control Arms?
Read the full article for a practical guide with clear decision-making framework mapped to evidence availability and cross-trial heterogeneity. Discover how to align your data with the right methodology to generate robust, payer-ready evidence that stands up to scrutiny.
Author
Dr. Chris Cameron is a global thought leader in health economics and outcomes research with over a decade of experience. Prior to joining EVERSANA, Chris was a partner at Cornerstone Research Group Inc., and…